In 2020 alone, almost 10 million people lost their battle against cancer. However, oncology company NovoCure (NASDAQ: NVCR) and its new category of cancer treatment is improving the lives of patients. And with 1,100% gains since its IPO, it's also improving investors' lives. If you're afraid that you've missed the boat, here are three reasons why NovoCure could still keep winning.
Over the past century, the basic methods for treating cancer have remained the same: surgery, chemotherapy, and radiation treatment. Unfortunately, these treatments are invasive, and they often damage both cancerous and healthy tissues, leading to side effects and additional health ailments.
Since its founding in 2000, NovoCure has instead pursued tumor-treating fields (TTF), in which low-powered electrical fields disrupt cancer cells' ability to multiply. In addition, NovoCure designed and brought to market its Optune System, a device that applies tumor treating fields to a patient as they wear it throughout the day.
For further details see:
Up 1,100%, This Cancer-Fighting Stock Has Room To Run